Ermium investors are from very diverse backgrounds : venture capital, industry and technology transfer bringing a wide range of complementary expertises
Kurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics and Kurma Diagnostics II, as well as via strategic partnerships with prestigious European research and medical institutions. Kurma has financed 45 companies since 2009 and has 470 M€ under management.
Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.
Domain Therapeutics is committed to discovering and developing innovative cancer immunotherapies, and treatments for neurologic disorders and rare diseases. It is a leading biopharmaceutical company in the field of G Protein- Coupled Receptors (GPCRs), one of the most important class of drug targets.
Domain Therapeutics identifies and develops candidates (allosteric modulators and biased ligands of GPCRs) through its innovative approach and technologies.
Erganeo is a French investment company specializing in disruptive innovations with a positive impact on our society.
Her mission is to accelerate and simplify partnerships between public research bodies and the industrial sector in the pursuit of progress that is ethical and sustainable.